15 results about "Ophthalmic preparations" patented technology

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

A solubilizing composition for the poorly soluble drug rebamipide, its preparation method and application, and the solubilizing method, by combining rebamipide with a phosphorylated drug in a specific ratio, effectively improves the solubility of rebamipide in PBS. The solubilizing composition prepared by this invention significantly improves the bioavailability of rebamipide, providing a new approach for the development of oral and ophthalmic formulations of rebamipide.

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

The application discloses an ophthalmic preparation and application thereof, and belongs to the technical field of ophthalmic preparations. The ophthalmic preparation comprises the following components: recombinant human beta nerve growth factor, hydrochloric acid histidine or citrate, polyvinyl alcohol or hydroxypropyl methyl cellulose, L-methionine, and a protective agent, wherein the protective agent is selected from one or more of trehalose, glycerol and amino acids; and the pH value of the ophthalmic preparation is 6.0-7.0. The ophthalmic preparation has good storage stability.

The application provides a kind of eye drop composition and its preparation method and application, belong to ophthalmic preparation technical field.The eye drop composition used in the application includes the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose, injection water;By compounding each component, a kind of eye drop capable of realizing brimonidine tartrate sustained release, prolonging the time of antihypertensive effect, and having the characteristics of reducing blinking discomfort, long-acting moisturizing, anti-inflammatory soothing, mild antiseptic, etc. is prepared;The eye drop of the application is helpful to glaucoma, high eye pressure, dry eye, postoperative inflammation or allergy, preservative-sensitive or preservative-allergic population, improves the quality of life, relieves the disease.

The present invention relates to an ophthalmic preparation and the use thereof. Specifically, the present invention relates to a pilocarpine ophthalmic preparation and the use thereof in the treatment of ocular diseases. The pilocarpine ophthalmic preparation provided in the present invention has the beneficial effects of a good stability and low ocular irritation.

The application discloses a surface-engineered Gouqi-source exosome ophthalmic preparation for treating ocular surface diseases, and belongs to the technical field of ocular surface drug delivery and plant-source exosome preparation. The preparation takes Gouqi-source exosomes as the main body, takes a mucin-related peptide-anchor molecule complex capable of combining with, adsorbing, intertwining or anchoring the ocular mucosa, epithelial sugar absorption or mucin network, and having an ocular surface repair effect as a surface modification unit, and is used for improving the residence capacity of the exosomes on the ocular surface and enhancing the ocular surface repair effect.

The present invention provides a gel-forming ophthalmic composition comprising povidone iodine, a steroid, a polysaccharide polymer gelling agent, water, and suitable excipients for ophthalmic preparations. This composition is not only stable, but also can effectively kill a variety of pathogens, rapidly alleviate associated signs and symptoms, and treat ocular diseases.

The invention provides ophthalmic compositions comprising about 0.1 % (w / v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.

The application discloses a kind of composite plant extract eye drops for relieving eye fatigue and a preparation method thereof, and relates to the technical field of ophthalmic preparations.The eye drops of the present application use lutein, zeaxanthin, blueberry extract, peppermint essential oil and borneol as fat-soluble active ingredients, and use phospholipid and poloxamer 188 as a composite nanocarrier, in combination with sodium hyaluronate, sodium chloride and a buffer system, a bacteriostatic system to form the eye drops.The present application uses a film hydration combined with high-pressure homogenization process to produce clear and transparent, thermodynamically stable eye drops, which solves the problems of low solubility, easy oxidative degradation and poor bioavailability of fat-soluble ingredients, improves the concentration and retention time of active ingredients in the eye, and the synergistic effect of various plant extracts can effectively relieve the symptoms of eye fatigue caused by long-term eye use, such as dryness, acid swelling, blurred vision and ciliary spasm, without eye irritation and with high stability.

The present application relates to the technical field of medicine, in particular to a flexible lipoic acid nano ophthalmic preparation for improving presbyopia, the flexible lipoic acid nano ophthalmic preparation contains a substance with a core-shell structure, the shell layer of the substance covers the core layer, the core layer is lipoic acid nano liposome, and the shell layer is dendritic PAMAM; the flexible lipoic acid nano ophthalmic preparation includes the following 100% by weight of raw materials: 0.5-2.5% of lipoic acid, 1-6% of soybean phospholipid, 0.1-0.7% of cholesterol, 0.2-0.6% of dendritic PAMAM, 0.1-0.4% of chitosan mixture, 1-3% of isotonicity regulator, 0.1-0.3% of softener, and the balance is water for injection, and further includes a non-ionic pH regulator to adjust the pH value of the preparation to 6.0-7.5. The preparation has superior corneal permeability, cell compatibility and biodegradability, and has a long drug release time.

This invention relates to a method for detecting metal particles in ophthalmic preparations and its application. The method includes squeezing the sample to be tested into the groove of a glass slide in a fixture, spreading it evenly, keeping it at a certain temperature, cooling and solidifying it, performing microscopic imaging, acquiring images of the effective filtration area, dividing the particle filter membrane into sections, acquiring images of each section, stitching the acquired images to generate an image of visible light signals, using a CNN model to identify insoluble particles, and analyzing the results. The fixture includes an outer frame fixing structure, transparent glass, and a coverslip. This invention employs pretreatment, processing the ophthalmic preparation beforehand, to more efficiently complete the detection of particles, foreign matter, and metals in the preparation, providing a safe and reliable intelligent detection solution for the quality monitoring of ophthalmic drug preparations.

The present disclosure relates to among other things, an ophthalmic formulation of a lipidated chemerin composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof, that is stable in terms of pH, osmolality, physical appearance, and purity of the chemerin composition, when stored under normal storage conditions. One aspect of the present disclosure also relates to use of the said ophthalmic formulation for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain.